Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoSTING-SN
- Development stage
- Preclinical
- Lead developer
- AuraVax Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
**NanoSTING-SN** is a preclinical intranasal, multi-antigen protein-subunit vaccine designed to prevent coronavirus infection, particularly COVID-19. It combines trimeric SARS-CoV-2 spike protein and SARS-CoV-2 nucleocapsid protein with NanoSTING, a liposomal nanoparticle adjuvant containing the endogenous STING agonist 2'-3' cGAMP. Local activation of STING in the nasal respiratory tract promotes innate antiviral signaling, while the spike and nucleocapsid antigens induce mucosal and systemic adaptive immunity. In animal studies, NanoSTING-SN eliminated detectable SARS-CoV-2 replication in lungs and nostrils after Delta challenge and prevented transmission of Omicron BA.5 to naïve hamsters; it also generated cross-reactive immune responses against related coronaviruses. ([nature.com](https://www.nature.com/articles/s41467-024-50133-2))
- Other names
- NanoSTING-Spike-Nucleocapsid
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on NanoSTING-SN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoSTING-SN.